The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hospital Costs

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hospital Costs


High impact information on Hospital Costs

  • RESULTS.--Neonatal hospital costs until medically cleared for discharge were $5200 more for cocaine-exposed infants than for unexposed infants (a difference of $7957 vs $2757 [P = .003]) [6].
  • CONCLUSIONS: The major determinants of total excess cost were the control risk of hospitalization, the proportional reduction in risk with HGF, and the average daily hospital cost [7].
  • RESULTS: Hospital costs from the time of first dose to discharge were significantly higher for all patients who received liposomal amphotericin B ($48,962 v $43,183; P =.022) [8].
  • Hospital costs were significantly higher for GM-CSF-treated patients if GM-CSF was included in the price (median costs, $4,140 [US] for GM-CSF v $590 for placebo; P < .05) [9].
  • Persons with RA in the worst quartile of function experienced total annual direct costs that were 2.55 times as high and total hospital costs that were 6.97 times as high as those in the best (e.g., the first) quartile [10].

Biological context of Hospital Costs


Anatomical context of Hospital Costs


Associations of Hospital Costs with chemical compounds


Gene context of Hospital Costs

  • Median hospital cost associated with treatment of patients with MRSA infections was higher compared with patients with MSSA infections ($16,575 vs $12,862; p = 0.11); however, this difference was not statistically significant [19].
  • Reports are rendered "as soon as possible" (ASAP) expediting appropriate clinical management and decreased length of stay and hospital costs [20].
  • Therefore, it appears that the benefits of MARS therapy are enough to justify the cost of treatment and safe hospital costs, at least in the described population [21].
  • There were no significant differences in the mean length of hospital stay (6.3 +/- 6.7 versus 6.2 +/- 6.8 days; P = 0.47) or hospital cost ($8,920 +/- $11,511 versus $7,785 +/- $7,643; P = 0.33) between the surgery and angioplasty groups [22].
  • Overall, recurrent hospital costs were significantly lower (14%) in the HBI group (mean +/- SD, 823 dollars +/- 1642 dollars vs 960 dollars +/- 1376 dollars per patient per year; P = .045) [23].

Analytical, diagnostic and therapeutic context of Hospital Costs


  1. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. de Lissovoy, G., Stier, D.M., Ciesla, G., Munger, M., Burger, A.J. Am. J. Cardiol. (2003) [Pubmed]
  2. Postoperative chest percussion with postural drainage in obese patients following gastric stapling. Torrington, K.G., Sorenson, D.E., Sherwood, L.M. Chest (1984) [Pubmed]
  3. Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation after cardiothoracic surgery. Gillespie, E.L., White, C.M., Kluger, J., Rancourt, J.A., Gallagher, R., Coleman, C.I. Pharmacotherapy (2006) [Pubmed]
  4. Randomized clinical outcome study of critically ill patients given glutamine-supplemented enteral nutrition. Jones, C., Palmer, T.E., Griffiths, R.D. Nutrition (Burbank, Los Angeles County, Calif.) (1999) [Pubmed]
  5. Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Ballatori, E., Roila, F., Berto, P., De Angelis, V., Neri, C., Olivieri, A., Tonato, M., Del Favero, A. PharmacoEconomics. (1994) [Pubmed]
  6. The neonatal costs of maternal cocaine use. Phibbs, C.S., Bateman, D.A., Schwartz, R.M. JAMA (1991) [Pubmed]
  7. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. Lyman, G.H., Lyman, C.G., Sanderson, R.A., Balducci, L. J. Natl. Cancer Inst. (1993) [Pubmed]
  8. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Cagnoni, P.J., Walsh, T.J., Prendergast, M.M., Bodensteiner, D., Hiemenz, S., Greenberg, R.N., Arndt, C.A., Schuster, M., Seibel, N., Yeldandi, V., Tong, K.B. J. Clin. Oncol. (2000) [Pubmed]
  9. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Vellenga, E., Uyl-de Groot, C.A., de Wit, R., Keizer, H.J., Löwenberg, B., ten Haaft, M.A., de Witte, T.J., Verhagen, C.A., Stoter, G.J., Rutten, F.F., Mulder, N.H., Smid, W.M., de Vries, E.G. J. Clin. Oncol. (1996) [Pubmed]
  10. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Yelin, E., Wanke, L.A. Arthritis Rheum. (1999) [Pubmed]
  11. Remifentanil, fentanyl, and cardiac surgery: a double-blinded, randomized, controlled trial of costs and outcomes. Myles, P.S., Hunt, J.O., Fletcher, H., Watts, J., Bain, D., Silvers, A., Buckland, M.R. Anesth. Analg. (2002) [Pubmed]
  12. Is the APOE epsilon4 genotype associated with higher hospital costs among elderly patients? Taylor, D.H., Fillenbaum, G., Burchett, B., Blazer, D.G. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. (2003) [Pubmed]
  13. Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Fanikos, J., Tsilimingras, K., Kucher, N., Rosen, A.B., Hieblinger, M.D., Goldhaber, S.Z. Am. J. Cardiol. (2004) [Pubmed]
  14. Computer modelling antibiotic therapy costs. Impact of therapeutic range. Gladen, H.E. Drugs (1988) [Pubmed]
  15. Health care financing policy for hospitalized nephrology patients. Muñoz, E., Barrau, L., Goldstein, J., Benacquista, T., Mulloy, K., Wise, L. Am. J. Kidney Dis. (1988) [Pubmed]
  16. The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Uyl-de Groot, C.A., Ossenkoppele, G.J., van Riet, A.A., Rutten, F.F. Eur. J. Cancer (1994) [Pubmed]
  17. Final report on the cost of treating arthritic disease: comparison between salicylates and nonsalicylate nonsteroidal anti-inflammatory drugs. Kolodny, A.L., Klipper, A. Semin. Arthritis Rheum. (1985) [Pubmed]
  18. Effect of antenatal administration of Betamethasone on hospital costs and survival of premature infants. Johnson, D.E., Munson, D.P., Thompson, T.R. Pediatrics (1981) [Pubmed]
  19. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Kopp, B.J., Nix, D.E., Armstrong, E.P. The Annals of pharmacotherapy. (2004) [Pubmed]
  20. Automated Speech-recognition Anatomic Pathology (ASAP) reporting. Teplitz, C., Cipriani, M., Dicostanzo, D., Sarlin, J. Seminars in diagnostic pathology. (1994) [Pubmed]
  21. Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs. Hassanein, T., Oliver, D., Stange, J., Steiner, C. Liver Int. (2003) [Pubmed]
  22. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). Hassan, S.A., Hlatky, M.A., Boothroyd, D.B., Winston, C., Mark, D.B., Brooks, M.M., Eagle, K.A. Am. J. Med. (2001) [Pubmed]
  23. Prolonged effects of a home-based intervention in patients with chronic illness. Pearson, S., Inglis, S.C., McLennan, S.N., Brennan, L., Russell, M., Wilkinson, D., Thompson, D.R., Stewart, S. Arch. Intern. Med. (2006) [Pubmed]
  24. Health care financing policy for hospitalized rheumatology patients. Munoz, E., Goldstein, J., Benacquista, T., Mulloy, K., Wise, L. J. Rheumatol. (1989) [Pubmed]
  25. Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. Kerstein, J., Soodan, A., Qamar, M., Majid, M., Lichstein, E., Hollander, G., Shani, J. Chest (2004) [Pubmed]
  26. The value of age and severity as predictors of costs in geriatric head trauma patients. Saywell, R.M., Woods, J.R., Rappaport, S.A., Allen, T.L. Journal of the American Geriatrics Society. (1989) [Pubmed]
  27. Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Coons, J.C., Seybert, A.L., Saul, M.I., Kirisci, L., Kane-Gill, S.L. The Annals of pharmacotherapy. (2005) [Pubmed]
  28. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. Gourevitch, M.N., Alcabes, P., Wasserman, W.C., Arno, P.S. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. (1998) [Pubmed]
WikiGenes - Universities